Antibody Response of 3-Dose COVID-19 Vaccination Schedule in Immunocompromised Patients With Hematologic Cancers

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, AUGUST 11, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.3227?guestAccessKey=0b9a95d7-73d1-49c0-a5a8-c690dae47ecc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081122

 

About The Study: In this study that included 584 immunocompromised patients with hematologic cancers, a third Moderna COVID-19 vaccination was associated with significantly improved SARS-CoV-2 antibody concentrations comparable to those obtained by healthy individuals after the standard two-dose Moderna vaccination schedule.

Authors: Mette D. Hazenberg, M.D., Ph.D., of the University of Amsterdam, is the corresponding author.

 

(doi:10.1001/jamaoncol.2022.3227)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.